Maxigen Biotech Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 159.43 million compared to TWD 162.64 million a year ago. Net income was TWD 41.37 million compared to TWD 42.1 million a year ago. Basic earnings per share from continuing operations was TWD 0.47 compared to TWD 0.47 a year ago. Diluted earnings per share from continuing operations was TWD 0.46 compared to TWD 0.47 a year ago.
For the nine months, sales was TWD 473.37 million compared to TWD 440.12 million a year ago. Net income was TWD 148.16 million compared to TWD 96.13 million a year ago. Basic earnings per share from continuing operations was TWD 1.67 compared to TWD 1.08 a year ago. Diluted earnings per share from continuing operations was TWD 1.66 compared to TWD 1.08 a year ago.